181 related articles for article (PubMed ID: 24722357)
1. Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters.
Dhar D; Toth K; Wold WS
Cancer Gene Ther; 2014 Apr; 21(4):171-8. PubMed ID: 24722357
[TBL] [Abstract][Full Text] [Related]
2. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters.
Dhar D; Spencer JF; Toth K; Wold WS
J Virol; 2009 Mar; 83(5):2130-9. PubMed ID: 19073718
[TBL] [Abstract][Full Text] [Related]
3. The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors.
Young BA; Spencer JF; Ying B; Tollefson AE; Toth K; Wold WS
Cancer Gene Ther; 2013 Sep; 20(9):521-30. PubMed ID: 23928731
[TBL] [Abstract][Full Text] [Related]
4. The effects of radiation on antitumor efficacy of an oncolytic adenovirus vector in the Syrian hamster model.
Young BA; Spencer JF; Ying B; Toth K; Wold WS
Cancer Gene Ther; 2013 Sep; 20(9):531-7. PubMed ID: 23928730
[TBL] [Abstract][Full Text] [Related]
5. Syrian hamster tumor model to study oncolytic Ad5-based vectors.
Dhar D; Toth K; Wold WS
Methods Mol Biol; 2012; 797():53-63. PubMed ID: 21948468
[TBL] [Abstract][Full Text] [Related]
6. Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model.
Dhar D; Spencer JF; Toth K; Wold WS
Mol Ther; 2009 Oct; 17(10):1724-32. PubMed ID: 19602998
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model.
Thomas MA; Spencer JF; Toth K; Sagartz JE; Phillips NJ; Wold WS
Mol Ther; 2008 Oct; 16(10):1665-73. PubMed ID: 18665155
[TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide enhances antitumor efficacy of oncolytic adenovirus expressing uracil phosphoribosyltransferase (UPRT) in immunocompetent Syrian hamsters.
Hasegawa N; Abei M; Yokoyama KK; Fukuda K; Seo E; Kawashima R; Nakano Y; Yamada T; Nakade K; Hamada H; Obata Y; Hyodo I
Int J Cancer; 2013 Sep; 133(6):1479-88. PubMed ID: 23444104
[TBL] [Abstract][Full Text] [Related]
9. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector.
Lichtenstein DL; Spencer JF; Doronin K; Patra D; Meyer JM; Shashkova EV; Kuppuswamy M; Dhar D; Thomas MA; Tollefson AE; Zumstein LA; Wold WS; Toth K
Cancer Gene Ther; 2009 Aug; 16(8):644-54. PubMed ID: 19197324
[TBL] [Abstract][Full Text] [Related]
10. New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster.
Spencer JF; Sagartz JE; Wold WS; Toth K
Cancer Gene Ther; 2009 Dec; 16(12):912-22. PubMed ID: 19478829
[TBL] [Abstract][Full Text] [Related]
11. Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors.
Thomas MA; Spencer JF; Wold WS
Methods Mol Med; 2007; 130():169-83. PubMed ID: 17401172
[TBL] [Abstract][Full Text] [Related]
12. INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies.
Ying B; Toth K; Spencer JF; Meyer J; Tollefson AE; Patra D; Dhar D; Shashkova EV; Kuppuswamy M; Doronin K; Thomas MA; Zumstein LA; Wold WS; Lichtenstein DL
Cancer Gene Ther; 2009 Aug; 16(8):625-37. PubMed ID: 19197322
[TBL] [Abstract][Full Text] [Related]
13. A hydrogel matrix prolongs persistence and promotes specific localization of an oncolytic adenovirus in a tumor by restricting nonspecific shedding and an antiviral immune response.
Jung BK; Oh E; Hong J; Lee Y; Park KD; Yun CO
Biomaterials; 2017 Dec; 147():26-38. PubMed ID: 28923683
[TBL] [Abstract][Full Text] [Related]
14. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
[TBL] [Abstract][Full Text] [Related]
15. Immunocompetent, semi-permissive cotton rat tumor model for the evaluation of oncolytic adenoviruses.
Toth K; Spencer JF; Wold WS
Methods Mol Med; 2007; 130():157-68. PubMed ID: 17401171
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
[TBL] [Abstract][Full Text] [Related]
17. A fully replication-competent adenovirus vector with enhanced oncolytic properties.
Toth K; Kuppuswamy M; Shashkova EV; Spencer JF; Wold WS
Cancer Gene Ther; 2010 Nov; 17(11):761-70. PubMed ID: 20596091
[TBL] [Abstract][Full Text] [Related]
18. A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity.
Tysome JR; Li X; Wang S; Wang P; Gao D; Du P; Chen D; Gangeswaran R; Chard LS; Yuan M; Alusi G; Lemoine NR; Wang Y
Clin Cancer Res; 2012 Dec; 18(24):6679-89. PubMed ID: 23091113
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression.
Rodríguez-García A; Giménez-Alejandre M; Rojas JJ; Moreno R; Bazan-Peregrino M; Cascalló M; Alemany R
Clin Cancer Res; 2015 Mar; 21(6):1406-18. PubMed ID: 25391696
[TBL] [Abstract][Full Text] [Related]
20. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.
Cerullo V; Diaconu I; Kangasniemi L; Rajecki M; Escutenaire S; Koski A; Romano V; Rouvinen N; Tuuminen T; Laasonen L; Partanen K; Kauppinen S; Joensuu T; Oksanen M; Holm SL; Haavisto E; Karioja-Kallio A; Kanerva A; Pesonen S; Arstila PT; Hemminki A
Mol Ther; 2011 Sep; 19(9):1737-46. PubMed ID: 21673660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
